VANCOUVER, BC / ACCESSWIRE / June 28, 2016 / Far Resources Ltd. (CSE: FAT) (“Far” or “the Company”) has further amended its option agreement (the “Amended Option Agreement“) with Redline Minerals Inc. (“Redline“), Redline Mining Corporation (“RMC“), and Southwest Land & Exploration Inc. (“SWLE“) (collectively, the “Optionors“) to acquire up to an 80% interest in and to 20 unpatented and 2 patented mineral claims located in Sierra County, New Mexico, U.S.A. known as the LG/Ivan and Little Granite unpatented mineral claims and the Ivanhoe/Emporia patented mineral claims known as the Winston Property (collectively the “Property“). See Far Resources’ news release dated February 1, 2016 for details.

Under the terms of the Amended Option Agreement, upon Far Resources having earned an initial 50% interest, it may elect to earn a further 30% interest by paying the Optionor an additional $180,000 cash, (reduced from $240,000 in the original agreement); issuing an additional 1,500,000 shares; and incurring an additional $900,000 (reduced from $1,500,000 in the original agreement) in Exploration Expenditures within three years of the election date.

Further to the update provided in the news release dated February 1, 2016, the Company has initiated permitting for an exploration program on the Little Granite claims to verify the results from work carried out in the 1980s in the Little Granite mine area. Sampling carried out by Far Resources in late 2013 confirmed the presence of abundant strongly mineralised epithermal vein material on the mine dumps, assumed to have been excavated during the decline development in the early 1980s. Two samples thought to be representative of the main style of quartz veining returned values of 179 g/t silver and 2.9 g/t gold and 170 g/t silver and 6.7 g/t gold respectively, while a third sample of grey, finer-grained quartz material returned values of 1,439 g/t silver and 25.2 g/t gold.

Limited drilling in 1984 returned several high grade vein intercepts (see news release dated February 1, 2016 for details). These results pre-date the implementation of NI 43-101, and since the work was not conducted under the supervision of a QP, cannot be relied upon and are presented as historical information only. However, the sampling conducted by Far suggests the results are credible and that further work using modern techniques and supervision is warranted.

Keith Anderson, President and CEO of Far Resources commented, “We are pleased that, together with Redline, we have been able to amend the agreement and create an environment that allows us to move this project forward.”

To date, the Company has made cash payments to Redline totaling $120,000 and has issued an aggregate total of 1,400,000 Common shares in the equity of the Company to satisfy its obligations, which are currently up to date. All other terms remain the same and are described in the Company’s disclosure documents available on SEDAR (www.sedar.com).

The technical content of this news release has been reviewed and approved by Lindsay Bottomer, P.Geo., an independent director of Far Resources Ltd. and a Qualified Person under NI 43-101.

Option Grant

The Company also wishes to announce that it has granted 500,000 stock options to certain officers, directors and consultants of the Company (the “Options“). The Options are exercisable into common shares (the “Shares“) of the Company at a price of $0.10 per Share for a period of five years from the date of grant.

About the Company

Far Resources Ltd. is an exploration company, publicly traded on the Canadian Securities Exchange under the symbol FAT, focused on the identification and development of high potential mineral opportunities in stable jurisdictions.

ON BEHALF OF THE BOARD OF DIRECTORS OF
FAR RESOURCES LTD.

Keith C. Anderson, President
President & CEO
604-805-5035

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward -looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Specifically, the Option Agreement is subject to numerous conditions and there are no assurances that all conditions will be satisfied or waived or that the acquisition of the Property will be successfully completed on the terms and conditions contemplated herein or at all. All of the forward-looking statements made in this news release are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

SOURCE: Far Resources Ltd.

ReleaseID: 441737

WINDSOR, ON / ACCESSWIRE / June 28, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a number of biotechs that are primed for a breakout as the market for smoking cessation products heats up.

Companies included: 22nd Century Group (XXII), Arena Pharamceuticals (ARNA), Gilla Inc (OTCMKTS: GLLA), Imperial Brands Plc (OTC: IMBBF)

According to a research report from Mintel, the United States smoking cessation market already exceeds $1 billion. Because an ever-increasing number of Americans are seeking effective ways to kick their nicotine habit, by 2017 smoking cessation products sales in the US are projected to top $1.2 billion and worldwide sales exceeding $3 billion. This should hardly come as a surprise as governments are tightening their smoking regulations, and more and more smokers are becoming aware of the long-term health effects of smoking.

For investors looking for a chance to cash in on the smoking cessation opportunity while it is still largely under the radar, 22nd Century Group (NYSE MKTS: XXII) is one company that should be carefully considered. This plant-based biotechnology company has come up with a revolutionary way of aiding smokers in their quest for a nicotine free lifestyle using the Company’s proprietary genetic engineering and plant breeding technology. With more than 200 patents in 96 countries controlling the genes in the tobacco plant responsible for nicotine production, 22nd Century is the only company in the world able to significantly increase or decrease the level of nicotine in naturally growing tobacco plants.

Low nicotine cigarettes encourage smokers to quit

From this technology, 22nd Century Group has developed both low and high nicotine cigarettes; these products are marketed under the ‘MAGIC’ and ‘RED SUN’ brand names respectively. It is important to note that the company’s Very Low Nicotine (VLN) smoking cessation cigarettes, code-named “X-22,” contain 20x less nicotine than conventional cigarettes (95% less nicotine than regular cigarettes made by traditional “Big Tobacco” companies). In fact, as a result of the Company’s monopoly on the genetic pathway in the tobacco plant responsible for nicotine production, 22nd Century is the only company in the world capable of producing combustible cigarettes containing naturally grown tobacco with non-addictive levels of nicotine.

In order to clearly appreciate the massive potential of these cigarettes, note that an independent clinical study – actually funded directly by the FDA last year – found that smokers who used 22nd Century’s proprietary Very Low Nicotine cigarettes went on to smoke fewer cigarettes per day and significantly increased quit rates. The withdrawal symptoms were also minimal signaling that lower nicotine intake could indeed prove far more effective to helping people stop smoking. The company is currently pursuing regulatory approval from the FDA to market X-22 as a prescription smoking cessation aid. When the Company announces the start of its Phase III trials, the high-visibility milestone could provide enough momentum for the Company’s stock to reach all-time highs (in excess of $6).

Modified risk cigarettes status will drive valuation

Apart from the huge opportunity in smoking cessation, 22nd Century Group also has another catalyst that will, without a doubt, play a significant role in increasing shareholder value. Like X-22, the company’s BRAND A Very Low Nicotine over-the-counter cigarettes contain approximately 95 percent less nicotine than conventional tobacco cigarettes, while 22nd Century’s BRAND B boasts of an extremely low “tar-to-nicotine” ratio. With these specifications, the company is seeking regulatory approval in the U.S. to market BRAND A and BRAND B as FDA authorized ‘reduced exposure’ or Modified Risk Tobacco Products (MRTP’s). To date, no other company has been authorized by the FDA to label and market tobacco products as Modified Risk. 22nd Century intends to be the first company in the world to win this important designation which could generate hundreds of millions of dollars in near-term licensing and product sales revenue.

Considering that the FDA has put in place regulations that prohibit the sale of all tobacco products with implied health claims or even with package labels that include the terms ‘light,’ or ‘ultra-light,’ or ‘low tar,’ 22nd Century’s Brand A FDA- authorized Modified Risk Tobacco Products labeling (which is expected this year) will be a major development to watch out for. According to research from the National Cancer Institute (NCI), before FDA banned the ‘light’ label, ‘light’ cigarettes commanded an impressive 83.5 percent of the tobacco market in 2005. This fact suggests that when 22nd Century group’s BRAND A is authorized by the FDA to actually be labeled and marketed as a reduced exposure tobacco product, the brand has the potential to capture a very lucrative piece of the $70 billion US cigarette market.

More companies to put on the watchlist

Arena Pharamceuticals (ARNA) is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. The company recently developed Lorcaserin, an investigational product for smoking cessation that shows plenty of promise going forward. Lorcaserin is a serotonin 2C receptor agonist which has demonstrated statistically significant improvement in reducing the number of patients who smoke after 12 weeks of treatment.

According to Aena’s CEO Jack Lief, the proof-of-concept trial provided what the company believes is the first clinical evidence that a selective serotonin 2C agonist may have a treatment effect for smoking cessation. The pre-clinical data suggest that Lorcaserin which selectively activates serotonin 2C receptors in the brain, may modulate the mesolimbic dopaminergic reward system helping smokers in their quite attempts.

Gilla Inc (OTCMKTS: GLLA) is a manufacturer, marketer and distributor of generic and premium branded e-liquid used in vaporizers, e-cigarettes, and other vaping hardware and accessories in Europe, Canada, and the U.S. While this company does not have a specific product tailored to help smokers quit, it does present a unique opportunity in the space that investors should consider. As mentioned earlier on, more smokers are looking for less harmful ways of getting their nicotine fix as they struggle to quit entirely which is where Gilla comes in. More smokers are turning to e-cigarettes and e-liquids for vaporizers to help them quit with the potential market rising to over $3 billion.

Imperial Brands Plc (OTC: IMBBF) is a well-known multinational tobacco company which has shown remarkable resilience in the face of a declining smoking population with the stock gaining 4 percent on an YTD basis. The company has solid growth prospects even as the tobacco industry comes under increasing government regulation with good reason. Imperial Brands is well exposed to the opportunity in reduced risk products with its e-cigarettes and with its massive financial power has the ability to acquire new innovative companies developing reduced risk tobacco products.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist, on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook, as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z.
Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader’s parent company has been compensated fifteen thousand dollars per month for a 12 month contract by 22nd Century Group. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage. Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

SOURCE: The Wealthy Biotech Trader

ReleaseID: 441736

LONDON, UK / ACCESSWIRE / June 28, 2016 / Active Wall ST announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Business Services industry. Companies recently under review include R.R. Donnelley, ServiceMaster Global, Vantiv, and Cintas. See our complete report on R.R. Donnelley at:

http://www.activewallst.com/registration-3/?symbol=RRD

Today, AWS is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/

Despite market downturns and stiff competition, outlook for the Business Services industry remains upbeat. Let us see how this is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at

http://www.activewallst.com/register/

Active Wall ST takes a brief technical look at how each of the aforementioned companies have fared over the last few trading sessions.

R.R. Donnelley & Sons Co. (NASDAQ: RRD)

On Monday, shares in Chicago, Illinois-based R.R. Donnelley & Sons Co. recorded a trading volume of 2.01 million shares, which was higher than their three months average volume of 1.57 million shares. The stock ended the day at $15.37, which was a decline of 2.97%. The Company’s shares have gained 8.26% since the start of this year. Shares of the Company, which enables organizations to communicate by creating, managing, producing, distributing, and processing content on behalf of its customers, is trading above its 200-day moving average by 1.55%. Furthermore, shares of R.R. Donnelley & Sons have a Relative Strength Index (RSI) of 36.79.

ServiceMaster Global Holdings Inc. (NYSE: SERV)

Memphis, Tennessee headquartered ServiceMaster Global Holdings Inc.’s stock finished yesterday’s session 1.97% higher at $38.27. A total volume of 4.01 million shares was traded, which was above their three months average volume of 1.46 million shares. The Company’s shares have gained 1.51% in the last one month and 4.42% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 1.21% and 2.99%, respectively. Furthermore, shares of ServiceMaster Global Holdings, which provides residential and commercial services in the U.S., have an RSI of 46.99. On June 14th, 2016, research firm Piper Jaffray reiterated its ‘Overweight’ rating with a decrease of the target price to $47 a share from $49 a share for the Company’s stock. The complimentary notes on SERV can be downloaded in PDF format at:

http://www.activewallst.com/registration-3/?symbol=SERV

Vantiv Inc. (NYSE: VNTV)

At the closing bell on Monday, shares in Cincinnati, Ohio headquartered Vantiv Inc. saw a slight drop of 0.66%, ending the day at $52.35. The stock recorded a trading volume of 2.44 million shares, which was above its three months average volume of 1.51 million shares. The Company’s shares have advanced 10.40% on an YTD basis. The stock is trading 4.00% above its 200-day moving average. Moreover, shares of Vantiv, which through its subsidiary, Vantiv Holding, LLC, provides electronic payment processing services to merchants and financial institutions in the U.S., have an RSI of 42.76. Register for free and access the latest research on VNTV at:

http://www.activewallst.com/registration-3/?symbol=VNTV

Cintas Corp. (NASDAQ: CTAS)

Cincinnati, Ohio headquartered Cintas Corp.’s stock ended the day 1.82% lower at $91.63. A total volume of 789,780 shares was traded, which was higher than their three months average volume of 643,940 shares. The Company’s shares have gained 2.21% over the previous three months and 0.64% since the start of this year. The stock is trading 2.76% above its 200-day moving average. Additionally, shares of Cintas, which provides corporate identity uniforms and related business services primarily in North America, Latin America, Europe, and Asia, have an RSI of 38.49. Get free access to your research report on CTAS at:

http://www.activewallst.com/registration-3/?symbol=CTAS

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441728

LONDON, UK / ACCESSWIRE / June 28, 2016 / Active Wall St announces its coverage of market signals with emphasize on 52-week high events which are an important milestone for any stock. For today’s coverage we are profiling the following equities: NextEra Energy, Inc. (NYSE: NEE), Hecla Mining Co. (NYSE: HL), Randgold Resources Limited (NASDAQ: GOLD), and Dollar General Corporation (NYSE: DG). Register with us now for your free membership and get more on our signal strategies at:

http://www.activewallst.com/register/

Stock Market Performance

On Monday, June 27, 2016, U.S Stock indexes declined sharply for a second day as the aftermath of the United Kingdom’s decision to leave the European Union continued to weigh on global markets.

The Dow Jones industrial average, declined 260.51 points, or 1.50%, closing at 17,140.24.

The S&P 500 closed lower by 1.81% at 2,000.54.

Additionally, the Nasdaq Composite lost 113.54 points, or 2.41%, to close at 4,594.44. The selloff continues Friday’s carnage when the market saw its steepest drop since August, 2015 after the U.K.’s decision to quit the EU, known as Brexit.

Today, AWS is promoting its market signals coverage with emphasis on NEE, HL, GOLD, and DG as they reach a new stock price milestone. Get all of our reports for free by signing up to http://www.activewallst.com/register/.

Even in this volatile environment there were a few stocks which managed to push to a new 52 week high; let us have a look at these equities below.

New 52- Week High – NextEra Energy

On Monday, shares in NextEra Energy, Inc. ended the day at $127.88, up 3.30%. During the session, the stock hit a new 52-week high of $128.22. The stock recorded trading volume of 3.4 million shares, which was above its three months average volume of 1.74 million shares.

Bloomberg reported yesterday that NextEra is in talks to buy Oncor Electric Delivery Co. and is closest to reaching a deal. The company’s shares are trading 6.98% and 17.94%, above their 50-day and 200-day moving averages respectively. NextEra’s stock price has advanced 8.24% in the previous three month and 24.93% since the beginning of 2016.

New 52- Week High – Hecla Mining

On Monday, Hecla Mining Co.’s stock oscillated between $4.60 and $4.87, hitting a new 52-week high of $4.87. The company’s stock recorded a trading volume of 12.01 million shares, which was above its three months average volume of 9.53 million shares.

On Monday, June 27, 2016, Hecla Mining announced an that it will make an acquisition offer for all of the remaining shares of Dolly Varden Silver Corporation, currently not owned by Hecla and its affiliates, for C$0.69 a share.

Over the last one month, Hecla Mining’s shares have gained 16.26%, and the stock has soared 150.20% since the beginning of 2016.

New 52- Week High – Randgold Resources Limited

Shares in Randgold Resources Limited surged 5.66% on Monday, finishing the day at $106.90. During the session, the stock hit a new 52-week high of $108.67. The company’s shares recorded a trading volume of 2.64 million shares, which was above its three months average volume of 951,080 shares. The stock oscillated between $104.27 and $1083.67 during the trading session.

A rise in gold prices helped to buoy shares of Randgold Resources as investors are looking for safe haven investment in light of the bearish market sentiment following the ‘Brexit’. Randgold Resources’ stock has climbed 24.16% in the past one month and 73.86% since the beginning of the year.

New 52- Week High – Dollar General

On Monday, Dollar General Corporation’s stock gained 1.50%, closing the day at $93.51, after hitting a new 52-week high of $93.78. The stock recorded a trading volume of 4.08 million shares, which was higher than its three months average volume of 2.70 million shares.

Dollar General’s stock is trading 8.88% and 23.99% above its 50-day and 200-day moving averages respectively. Furthermore, the shares of the company are trading at 22.56 times their trailing twelve month P/E ratio. Over the past one month, Dollar General’s shares have gained 6.54% and are up 30.85% since the beginning of this year.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441731

LONDON, UK / ACCESSWIRE / June 28, 2016 / Active Wall St announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Utilities sector. Companies recently under review include Entergy, OGE Energy, Companhia Paranaense de Energia, and CPFL Energia. See our complete report on Entergy at:

http://www.activewallst.com/registration-3/?symbol=ETR

Today, AWS is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

The S&P 500 Utilities sector rose to a record high yesterday despite uncertainties enveloping the Street following the U.K. exit from the European Union. Let us see how this is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at:

http://www.activewallst.com/register/

Active Wall St takes a brief look at how each of the companies mentioned above have performed at the close yesterday and over the last few trading sessions.

Entergy Corp. (NYSE: ETR)

At the close on Monday, shares in New Orleans, Louisiana-based Entergy Corp. gained 1.18%, ending the day at $78.91. The stock recorded a trading volume of 1.32 million shares. The Company’s shares have advanced 4.41% in the last one month, 0.23% in the previous three months, and 18.13% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.67% and 12.47%, respectively. Moreover, shares of Entergy, which together with its subsidiaries, engages in the generation and distribution of electricity in the U.S., have a Relative Strength Index (RSI) of 64.25.

OGE Energy Corp. (NYSE: OGE)

Shares in Oklahoma City, Oklahoma headquartered OGE Energy Corp. ended the day 1.24% lower at $31.07. A total volume of 1.71 million shares was traded, which was above their three months average volume of 1.29 million shares. In the last month and the previous three months, the stock has gained 1.90% and 9.52%, respectively. Moreover, the Company’s shares have advanced 20.61% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.04% and 13.91%, respectively. Furthermore, shares of OGE Energy, which together with its subsidiaries, operates as an energy and energy services provider that offers physical delivery and related services for electricity and natural gas primarily in the south central U.S., have an RSI of 54.99. Visit us today and download your complimentary research report on OGE at:

http://www.activewallst.com/registration-3/?symbol=OGE

Companhia Paranaense de Energia – COPEL (NYSE: ELP)

On Monday, shares in Curitiba, Brazil headquartered Companhia Paranaense de Energia finished 0.81% lower at $8.56 and with a total volume of 272,820 shares traded. The stock has advanced 25.51% in the last one month, 10.17% over the previous three months, and 52.21% on an YTD basis. The Company’s shares are trading above their 50-day and 200-day moving averages by 13.35% and 22.28%, respectively. Additionally, shares of COPEL, which engages in the generation, transmission, distribution, and sale of electricity to industrial, residential, commercial, rural, and other customers primarily in the State of Paran, Brazil, have an RSI of 63.45. The research report on ELP is available for free at:

http://www.activewallst.com/registration-3/?symbol=ELP

CPFL Energia S.A. (NYSE: CPL)

Sao Paulo, Brazil headquartered CPFL Energia S.A.’s shares recorded a trading volume of 652,760 shares at the end of yesterday’s session, which was higher than their three months average volume of 552,600 shares. The stock closed the day at $11.78, which was a correction of 1.09%. The Company’s shares have advanced 15.60% in the last one month, 10.00% over the previous three months, and 64.41% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.90% and 33.34%, respectively. Additionally, shares of CPFL Energia, which together with its subsidiaries, generates, transmits, distributes, and commercializes electricity to industrial, residential, commercial, rural, and other consumers; and provides energy-related services in Brazil, have an RSI at 58.11. Complimentary research on CPL is accessible at:

http://www.activewallst.com/registration-3/?symbol=CPL

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441727

LONDON, UK / ACCESSWIRE / June 28 2016 / Active Wall St announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Industrial Metals & Minerals industry. Companies recently under review include Vale, Cliffs Natural Resources, Teck Resources, and Rio Tinto. See our complete report on Vale at:

http://www.activewallst.com/registration-3/?symbol=VALE

Today, AWS is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/

The Industrial Metals and Minerals industry continues to recover given a stronger dollar and global economy. Let us see how this is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at

http://www.activewallst.com/register/

Active Wall St takes a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions.

Vale S.A. (NYSE: VALE)

Rio de Janeiro, Brazil headquartered Vale S.A.’s shares saw a decline of 3.74% and finished Monday’s trading session at $4.38. A total volume of 18.26 million shares was traded. In the last month and the previous three months, the stock has advanced 7.88% and 6.31%, respectively. Additionally, the Company’s shares have gained 33.13% since the start of this year. The stock is trading above its 200-day moving average by 10.30%. Moreover, shares of Vale, which together with its subsidiaries, engages in the research, production, and sale of iron ore and pellets, nickel, fertilizer, copper, coal, manganese, ferroalloys, cobalt, platinum group metals, and precious metals in Brazil and globally, have a Relative Strength Index (RSI) of 44.45. On June 09th, 2016, research firm Goldman initiated a ‘Neutral’ rating for the Company’s stock.

Cliffs Natural Resources Inc. (NYSE: CLF)

On Monday, shares in Cleveland, Ohio headquartered mining and natural resources Company, Cliffs Natural Resources Inc. recorded a trading volume of 10.95 million shares, and ended the session 6.44% lower at $4.65. The stock has gained 40.06% in the last one month, 54.49% in the previous three months, and 194.30% on an YTD basis. The Company’s shares are trading 10.88% above their 50-day moving average and 62.52% above their 200-day moving average. Furthermore, shares of Cliffs Natural Resources, which produces and supplies iron ore, have an RSI of 46.96. On June 10th, 2016, research firm Macquarie upgraded the Company’s stock rating from ‘Neutral’ to ‘Outperform’. The research firm also revised upwards its previous target price from $4 to $7.50. The complimentary research on CLF can be activated at:

http://www.activewallst.com/registration-3/?symbol=CLF

Teck Resources Ltd (NYSE: TCK)

Shares in Vancouver, Canada-based Teck Resources Ltd closed the day at $11.41, down 3.22%. The stock recorded a trading volume of 8.68 million shares. The Company’s shares have advanced 18.52% in the last one month, 55.35% over the previous three months, and 196.61% since the start of this year. The stock is trading 7.16% above its 50-day moving average and 70.63% above its 200-day moving average. Additionally, shares of Teck Resources, which explores, develops, and produces natural resources in the Americas, the Asia Pacific, and Europe, have an RSI of 50.15. Register for free and access the latest research report on TCK at:

http://www.activewallst.com/registration-3/?symbol=TCK

Rio Tinto PLC (NYSE: RIO)

At the closing bell yesterday, shares in London, the U.K. headquartered mining and metals Company, Rio Tinto PLC ended 2.61% lower at $28.01. A total volume of 5.70 million shares was traded, above their three months average volume of 4.78 million shares. The stock has advanced 1.49% in the previous three months and 0.02% on an YTD basis. The Company’s shares are trading below their 200-day moving average by 6.17%. Furthermore, shares of Rio Tinto, which finds, mines, and processes mineral resources, have an RSI of 41.85. Yesterday, research firm Goldman upgraded the Company’s stock rating from ‘Sell’ to ‘Neutral’. The complete research report on RIO is available for free at:

http://www.activewallst.com/registration-3/?symbol=RIO

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441720

LONDON, UK / ACCESSWIRE / June 28, 2016 / Active Wall St announces its coverage of market signals with highlight on these most active stocks from Monday’s session: The AES Corporation (NYSE: AES), People Corporation (NYSE: PPL), and Exelon Corporation (NYSE: EXC).Register with us now for your free membership and get more on our signal alerts at:

http://www.activewallst.com/register/

Stock Market Performance
On Monday, June 27, 2016, U.S Stock indexes declined sharply for a second day as the aftermath of the United Kingdom’s decision to leave the European Union continued to weigh on global markets.

The Dow Jones industrial average, declined 260.51 points, or 1.50%, closing at 17,140.24.

The S&P 500 closed lower by 1.81% at 2,000.54.

Additionally, the Nasdaq Composite lost 113.54 points, or 2.41%, to close at 4,594.44. The selloff continues Friday’s carnage when the market saw its steepest drop since August, 2015 after the U.K.’s decision to quit the EU, known as Brexit.

Today, AWS is promoting its market signals coverage with emphasis on AES, PPL, and EXC. Get all of our reports for free by signing up to http://www.activewallst.com/register/
Here we take a look at some of the most active share in the Technology Sector.

Most Active – AES Corporation

On Monday, shares in AES Corp. recorded heavy trading volume of 10.44 million shares, higher than its three months average volume of 4.69 million shares. AES’s stock ended the trading session at $11.41, down 4.04%. The stock moved between an intraday range of $11.29 and $11.74. AES’s shares traded at 26.85 times its trailing twelve month P/E ratio.

The stock is up 4.78% in the last one month and 21.85% on YTD basis. The company’s stock is trading 1.72% above its 50-day moving average and 11.31% above its 200-day moving average.

Most Active – People Corporation

Shares of People Corp. finished Monday’s trading session 1.64% lower, at $36.57. A total of 8.93 million shares were traded, which was above its three months average volume of 4.43 million shares. The stock moved between $36.34 and $37.04 during the session.

Since the beginning of 2016, the company’s stock has advanced 9.35%. The company’s shares are trading 1.72% above its 50-day average and 11.31% above its 200-day moving average. The stock traded at 48.25 times its trailing twelve month P/E ratio.

Most Active – Exelon

On Monday, shares in Exelon Corporation oscillated between $33.93 and $34.71 before ending the session at $34.59, up 0.58%. Exelon’s shares recorded a trading volume of 7.96 million shares, which was above its three months average volume of 5.19 million shares.

Shares of the company traded at 17.93 times its trailing twelve month P/E ratio. Exelon’s shares have declined 2.20% in the previous three months; however the stock has gained 26.93% on a YTD basis. The stock is trading 0.28% above its 50-day moving average; while it is 12.08% above its 200-day moving average.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441730

WINDSOR, ON / ACCESSWIRE / June 28, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight five biotechs whose pipelines have blockbuster potential for multiple cancer indications.

Companies included: Advanced Medical Isotopoe (ADMD); Aaptimmune Therapeutics (ADAP); Aduro Biotech (ADRO); Ariad Pharmaceuticals (ARIA)

A recently conducted study revealed that novel and new therapies led to a dramatic increase in global cancer treatment spending last year. According to the report from IMS Health, the global oncology drug market exploded to $107 billion in 2015 posting an 11.5 percent increase compared to the prior year and is expected to reach about $150 billion by 2020. The same report estimates that the cost of cancer drugs in the U.S rose by nearly $16 billion since 2010 driven by the uptake of new treatments approvals.

Going forward, this trend of increasing costs of cancer drugs will continue more so as targeted, personalized treatments increase in popularity. For instance there is a new type of cancer therapy designed to disable the PD-1 protein that tumors use to evade the immune system, which has been gathering a lot of media attention. The FDA has already approved such treatments from Roche Holding, Merck & Co. and Bristol-Myers Squibb each with an average retail price tag of $150,000 per year but this hasn’t stopped other companies from pursuing similar treatments.

The need for unique treatment options

As a matter of fact, Dr. Richard Pazdur, head of the FDA’s office of oncology products has expressed concerns that even as new drug makers race to bring new cancer treatments to market, a huge number of them are developing similar medicines. This means that companies developing unique cancer treatments for different types of tumors such as Advanced Medical Isotope (OTC: ADMD) are more likely to see their treatments pass the FDA’s evaluation expeditiously.

ADMD, a late stage radiation oncology focused medical device maker has taken a unique approach to treating multiple types of cancers through its brachytherapy approach which utilizes yttrium-90 (Y-90) RadioGel device. Brachytherapy basically uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area and with the development of RadioGel, this has been made much easier.

The Y-90 RadioGel is injectable into non operable tumors where it then focusses all the radiation on the target area as a result of the short range of beta particles from Y-90 causing as little damage as possible to the neighboring healthy cells. Currently, the device is awaiting FDA approval as a class II medical device which if granted will see its usage accelerate to save lives. The device’s safety profile will also be a great selling point due to the short half-life of beta particles and the potentially lower costs of Y-90.

Aaptimmune Therapeutics (NASDAQ: ADAP) is a clinical stage biotechnology company with multiple trials ongoing in solid tumors, hematologic cancer types and in cancers where survival rates for patients can be very limited. The company’s proprietary T-cell engineering platform has generated a strong pipeline of affinity enhanced T-cell therapies as well as an enhanced risk/benefit profile.

Adaptimune’s lead T-cell therapy targets the NY-ESO peptide which is present across multiple cancer types. The NY-ESO TCR targets the NY-ESO-1 target peptide – one of the best-characterized and frequently expressed by tumors of different origins and in advanced tumors. The NY-ESO TCR therapeutic candidate is being developed in partnership with GSK and is in multiple phase 1/2 clinical trials in patients with tumors and hematological malignancies including synovial sarcoma, multiple myeloma, melanoma and ovarian cancer.

Aduro Biotech (NASDAQ: ADRO) a cancer immunotherapy company with multiple therapeutic approaches in development is also on track to bring a new cancer treatment for multiple indications to market. The company’s lead technology platforms are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and STING Pathway Activators. The company’s LADD platform technology is our proprietary method of engineering Listeria mononcytogenes bacteria into therapeutic agents that stimulate targeted immune response to specific tumor antigens.

The first LADD therapeutics are engineered to stimulate an immune response to mesothelin, a tumor associated antigen expressed by multiple tumors types. Clinical trials are underway to ascertain the efficacy of this therapy on tumors in pancreatic, non-small cell lung and ovarian cancers and mesothelioma.

Ariad Pharmaceuticals (NASDAQ: ARIA) is an orphan oncology company focused on developing break through therapies for cancer patients and is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat orphan cancers. The company’s lead and only approved product is Iclusig for the treatment of adult patients with T315I-positive chronic myeloid leukemia as well as treatment of chronic phase, accelerated phase, or blast phase chronic myeloid leukemia for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.

Iclusig generated net product revenue of $112.5 million in FY2015 effectively doubling prior year revenue based on the indications mentioned above and does not expect to stop there. The company is already looking for ways to expand Iclusig’s market opportunities and is already pursuing another indication for the treatment. It presented proof-of-concept clinical trial data of Iclusig in adult patients with refractory metastatic and/or non resectable gastrointestinal stromal tumors initiated or re-opened multiple investigator sponsor trials in various cancers, including RET driven NSCLC which if approved could see its top line rise significantly.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist, on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook, as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z.
Follow us on Twitter:@Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader may from time to time outsource copywriting for these articles and does not accept responsibility for mistakes written by 3rd party writers as readers should always verify all statements. The Wealthy Biotech Trader’s parent company was compensated $50,000 as well as 100,000 restricted preferred shares by Advanced Medical Isotope Corporation. Wealthy Biotech Trader has since renewed their contract with Advance Medical Isotope for 6 months for either 4,000,000 restricted common shares per month or $20,000 per month, at the discretion of The Wealthy Biotech Trader’s parent company. Readers should understand that they will convert these preferred shares into common shares sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements.” Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage. Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

SOURCE: The Wealthy Venture Capitalist

ReleaseID: 441734

MONTREAL, QC / ACCESSWIRE / June 28, 2016 / Earth Alive Clean Technologies Inc. (CSE: EAC) (“Earth Alive” or the “Company”) announces it has signed an exclusive distribution agreement with IM-EX Global Trading for the Company’s patent-pending and certified organic biofertilizer, Soil Activator™.

IM-EX Global Trading is a company controlled by Mr. Félicien Mutalikanwa, the founder of Kigali based BraMin and Minimex Corporations. In addition to Rwanda, the agreement covers other East African countries such as Uganda, Tanzania, Burundi, Kenya, Zambia, Ethiopia, South Sudan, Mozambique, Malawi, and Zimbabwe.

“We are extremely pleased to have reached this agreement with IM-EX, which is the result of the proven performance of the Earth Alive biofertilizer in the local growing conditions of East Africa,” stated David Gilmour, CEO of Earth Alive. “With the signature of this agreement, IM-EX Global Trading has placed its first order of close to $200,000 of Soil Activator, and we anticipate that monthly shipments of our product will ramp up as the region discovers the benefits our product offers for a wide range of crops and soils.”

Félicien Mutalikanwa stated, “After more than six months of field testing and evaluating Soil Activator in combination with our farms’ best practices, we found that Soil Activator boosted productivity by significant amounts — such as a 27% overall yield increase in maize.” Mr. Mutalikanwa continued, “With results like this, we are proud to be the first to introduce this cutting-edge technology to East Africa — a region where agricultural activity will increase substantially in the years to come and where Soil Activator can provide a much needed boost in productivity. Quality organic fertilizers such as Soil Activator are a necessity for the region to meet increasing demand. As soon as this first shipment of Soil Activator arrives in Kigali this summer, we will begin using it in country and on BraMin Farms to further increase our yields, as well as to showcase the technology’s performance to the agriculture communities of Rwanda and adjoining countries. Soil Activator is a remarkable product and we have great plans for it in East Africa.”

Michael Warren, VP Global Operations, Agriculture Solutions, said, “We have been working closely with Félicien and his agronomists throughout their trial and evaluation period. Now that they have seen the results first hand, the enthusiasm they have for delivering Soil Activator into East Africa is remarkable. The momentum in Africa is growing, and we have already begun implementing trials in many countries across the continent, including in Burkina Faso, Ghana, Cameroun, Benin, and Côte d’Ivoire. We intend to build on our success with Félicien and his team in the months ahead.” Mr. Warren further added, “After having gained scientific and market validation in Canada, earlier this year Earth Alive opened up the Latin American market, and progress there continues as per our expectations. We aim to repeat that achievement in the dynamic African context.”

About Earth Alive Clean Technologies:

Earth Alive aims to be a key player in world markets of environmentally sustainable industrial solutions. The company works with the latest innovations in microbial technology to formulate and patent innovative products that can tackle the most difficult industrial challenges, once only reserved to environmentally harmful chemicals and additives. The company is focused on environmental sustainability in 1) the agriculture industry and 2) dust control for the mining industry.

About BraMin:

Established in 2008, BraMin Ltd is a joint venture between Bralirwa (Heineken Beer’s subsidiary in Rwanda) and Minimex (ProDev Holding subsidiary). BraMin runs a fully mechanized and irrigated 450-hectare farm. On one hand, this farm is part of ProDev Holding’s plan to have a vertically integrated supply chain; on the other hand, it is in line with Heineken’s local sourcing policy of securing at least 60% of raw materials within the country where its subsidiary operates.

About Minimex:

Created in 2002, Minimex is the largest maize mill in Rwanda, and its focus is on the production, marketing, and distribution of maize products. With a capacity of 45,000 metric tons per year, it operates a state of the art mill, and produces three products destined to three different target markets such as:

• Maize grits (20% of output), for the brewing industry
• Maize bran (30% of output), for the livestock industry
• Maize flour (50% of output), for human consumption

For additional company information, please visit: www.earthalivect.com

The CSE has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Information

Except for statements of historical fact, this news release contains certain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate” and other similar words, or statements that certain events or conditions “may” occur. Although Earth Alive believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.

Earth Alive Clean Technologies Inc.,
1001, Lenoir Street, Suite B-338,
Montreal (Qc) Canada
H4C 2Z6
T.(438) 333-1680

For media information and interview requests, please contact:
Mr. David Gilmour
(e) dgilmour@earthalivect.com
(p) 514-814-2899

For investor relations, please contact:
Mr. Frédérick Chabot
(e) frederick@contactfinancial.com
(p) 438-863-7071

SOURCE: Earth Alive Clean Technologies Inc.

ReleaseID: 441735